KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) EBT Margin (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed EBT Margin for 11 consecutive years, with 14414.89% as the latest value for Q3 2024.

  • On a quarterly basis, EBT Margin rose 1469983.0% to 14414.89% in Q3 2024 year-over-year; TTM through Dec 2024 was 290566.67%, a 29065481.0% decrease, with the full-year FY2024 number at 4054.42%, up 359843.0% from a year prior.
  • EBT Margin was 14414.89% for Q3 2024 at Palvella Therapeutics, up from 69533.33% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 14414.89% in Q3 2024 to a low of 69533.33% in Q2 2024.
  • A 5-year average of 3358.48% and a median of 181.83% in 2022 define the central range for EBT Margin.
  • Biggest YoY gain for EBT Margin was 1469983bps in 2024; the steepest drop was -6954600bps in 2024.
  • Palvella Therapeutics' EBT Margin stood at 817.06% in 2020, then surged by 88bps to 99.36% in 2021, then tumbled by -83bps to 181.83% in 2022, then skyrocketed by 80bps to 37.0% in 2023, then skyrocketed by 39063bps to 14414.89% in 2024.
  • Per Business Quant, the three most recent readings for PVLA's EBT Margin are 14414.89% (Q3 2024), 69533.33% (Q2 2024), and 5395.74% (Q1 2024).